Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

Affiliations

¹ Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. wadden@pennmedicine.upenn.edu.
² Johns Hopkins School of Nursing, Baltimore, MD, USA.
³ Division of Endocrinology and Metabolism, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
⁴ Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁵ Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.
⁶ Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Department of Pediatrics, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.
⁷ Vanderbilt Weight Loss Clinics, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ Obesity Group, Department of Endocrinology, Universidade de São Paulo, São Paulo, Brazil.
⁹ Eli Lilly and Company, Indianapolis, IN, USA.

Published Erratum

Thomas A Wadden et al. Nat Med. 2024 Jun.

. 2024 Jun;30(6):1784.

doi: 10.1038/s41591-024-02883-1.

¹ Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. wadden@pennmedicine.upenn.edu.
² Johns Hopkins School of Nursing, Baltimore, MD, USA.
³ Division of Endocrinology and Metabolism, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
⁴ Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁵ Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.
⁶ Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Department of Pediatrics, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.
⁷ Vanderbilt Weight Loss Clinics, Vanderbilt University Medical Center, Nashville, TN, USA.
⁸ Obesity Group, Department of Endocrinology, Universidade de São Paulo, São Paulo, Brazil.
⁹ Eli Lilly and Company, Indianapolis, IN, USA.

No abstract available

Erratum for

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Wadden TA, et al. Nat Med. 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15. Nat Med. 2023. PMID: 37840095 Free PMC article. Clinical Trial.